Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MetaVia Inc.GEMP · Entity 7947 | Director · President & CEO | November 25, 2016 | November 29, 2016 |
| Opus Genetics, Inc.OCUP · Entity 5892 | Director · President and CEO | December 31, 2022 | February 14, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MetaVia Inc.
Report date November 25, 2016 · Filed November 29, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.00 · Expires 2026-08-03 | Direct | 600,000 |
Reported balance
After 2016-11-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2016-11-25 · Grant · Acquired 120,000 · Balance 600,000 F1: The reporting person was granted an option to purchase 600,000 shares of common stock effective August 4, 2016. 360,000 of the shares underlying the option award were immediately earned on the date of the grant, 120,000 shares underlying the option award were earned on September 30, 2016 following the initiation of the Company's first clinical trial and 120,000 shares underlying the option award are earned upon the initiation of the Company's second clinical trial. The Company has initiated its second clinical trial, so the 120,000 shares underlying the option award that were subject to the initiation of the Company's second clinical trial have been earned. F2: The option vests in 48 equal consecutive monthly increments, so that all of the shares will be vested on the fourth anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person was granted an option to purchase 600,000 shares of common stock effective August 4, 2016. 360,000 of the shares underlying the option award were immediately earned on the date of the grant, 120,000 shares underlying the option award were earned on September 30, 2016 following the initiation of the Company's first clinical trial and 120,000 shares underlying the option award are earned upon the initiation of the Company's second clinical trial. The Company has initiated its second clinical trial, so the 120,000 shares underlying the option award that were subject to the initiation of the Company's second clinical trial have been earned.
F2: The option vests in 48 equal consecutive monthly increments, so that all of the shares will be vested on the fourth anniversary of the date of grant.
Opus Genetics, Inc.
Report date December 31, 2022 · Filed February 14, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 296,045 |
Ending reported balance
After 2022-12-27 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-12-23 · Gift · Disposed 30,000 · Balance 396,045 Row 2 · 2022-12-27 · Gift · Disposed 100,000 · Balance 296,045 |
| Common StockSEC Table I · non-derivative | IndirectHeld by Daughter | 50,000 |
Reported balance
After 2022-12-27 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2022-12-27 · Gift · Acquired 50,000 · Balance 50,000 |
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
BIOVIE INC.
Report date June 30, 2020 · Filed October 22, 2020
Section 16 reporting ended · disclosed 2020-10-22. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 10, 2023 Filed Jan 12, 2023 18:08 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | GrantEmployee Stock Option (right to buy) · Derivative | 201,683 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0001140361-23-001520 · form4.xml · derivative · entry 3 Sooch Mina · CIK 0001674006 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,683 Underlying: Common Stock · 201,683 shares Expires 2033-01-09 F2 · derivative.exercise_date: The option will vest with respect to 50,420 shares on January 10, 2024, with the balance vesting quarterly in twelve equal installments thereafter. Read SEC document |
| January 10, 2023 Filed Jan 12, 2023 18:08 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | GrantCommon Stock | 134,456 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-001520 · form4.xml · nonDerivative · entry 1 Sooch Mina · CIK 0001674006 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 430,501 F1 · shares: Represents a grant of restricted stock units which vest in four equal installments on the first, second, third and fourth anniversary of the grant date of January 10, 2023. Read SEC document |
| December 27, 2022 Filed Feb 14, 2023 14:05 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | GiftCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-006840 · form5.xml · nonDerivative · entry 3 Sooch Mina · CIK 0001674006 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Held by Daughter Disclosed balance after: 50,000 Read SEC document |
| December 27, 2022 Filed Feb 14, 2023 14:05 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | GiftCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-006840 · form5.xml · nonDerivative · entry 2 Sooch Mina · CIK 0001674006 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 296,045 Read SEC document |
| December 23, 2022 Filed Feb 14, 2023 14:05 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | GiftCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-006840 · form5.xml · nonDerivative · entry 1 Sooch Mina · CIK 0001674006 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 396,045 Read SEC document |
| September 06, 2022 Filed Sep 8, 2022 16:01 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | OtherSeries B Warrant (right to buy) · Derivative | 1,023 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-032758 · form4.xml · derivative · entry 2 Sooch Mina · CIK 0001674006 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,023 shares Expires 2022-09-07 F1 · derivative.expiration_date: The expiration date of the Series B Warrants occurred on the later of (x) the Reservation Date (as defined in the Series B Warrants) and (y) the date on which the Series B Warrant has been exercised in full. Read SEC document |
| September 06, 2022 Filed Sep 8, 2022 16:01 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | OtherCommon Stock | 1,023 | $0.00 | $0.10 |
DisclosureSEC source: 0001140361-22-032758 · form4.xml · nonDerivative · entry 1 Sooch Mina · CIK 0001674006 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 426,045 Read SEC document |
| May 20, 2022 Filed May 23, 2022 16:58 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | PurchaseCommon Stock | 12,500 | $2.02 | $25,300.00 |
DisclosureSEC source: 0001140361-22-020274 · form4.xml · nonDerivative · entry 2 Sooch Mina · CIK 0001674006 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 425,022 F2 · price: The price represents the weighted average price of the multiple transactions reported on this line. The shares were purchased at prices ranging from $2.015 to $2.025. Upon request by the SEC staff, the issuer or any securityholder of the issuer, the reporting person will provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| May 19, 2022 Filed May 23, 2022 16:58 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | PurchaseCommon Stock | 12,500 | $2.07 | $25,878.75 |
DisclosureSEC source: 0001140361-22-020274 · form4.xml · nonDerivative · entry 1 Sooch Mina · CIK 0001674006 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 412,522 F1 · price: The price represents the weighted average price of the multiple transactions reported on this line. The shares were purchased at prices ranging from $2.045 to $2.10. Upon request by the SEC staff, the issuer or any securityholder of the issuer, the reporting person will provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| January 28, 2022 Filed Feb 1, 2022 16:26 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | GrantEmployee Stock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001140361-22-003495 · form4.xml · derivative · entry 1 Sooch Mina · CIK 0001674006 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2032-01-27 F1 · derivative.exercise_date: The option will vest with respect to 50,000 shares on January 28, 2023, and then with respect to 4,166 shares on the last day of each month from February 2023 through December 2025 and with respect to 4,190 shares at the end of January 2026. Read SEC document |
| November 19, 2020 Filed Nov 25, 2020 19:26 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | PurchaseSeries B Warrant (right to buy) · Derivative | 2,046 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001140361-20-026646 · form4.xml · derivative · entry 3 Sooch Mina · CIK 0001674006 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,046 Underlying: Common Stock · 2,046 shares Expires 2022-01-28 F2 · shares: Subject to adjustment based on certain price reset provisions. F1 · price: The Reporting Person purchased shares, Series A Warrants and Series B Warrants as part of a private placement for an aggregate price of $65,000. Read SEC document |
| November 19, 2020 Filed Nov 25, 2020 19:26 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | PurchaseSeries A Warrant (right to buy) · Derivative | 17,413 | Not disclosed Strike: $4.48 | Not disclosed |
DisclosureSEC source: 0001140361-20-026646 · form4.xml · derivative · entry 2 Sooch Mina · CIK 0001674006 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,413 Underlying: Common Stock · 17,413 shares Expires 2025-11-19 F2 · derivative.exercise_price: Subject to adjustment based on certain price reset provisions. F1 · price: The Reporting Person purchased shares, Series A Warrants and Series B Warrants as part of a private placement for an aggregate price of $65,000. Read SEC document |
| November 19, 2020 Filed Nov 25, 2020 19:26 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | PurchaseCommon Stock | 11,524 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-20-026646 · form4.xml · nonDerivative · entry 1 Sooch Mina · CIK 0001674006 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 800,044 F1 · price: The Reporting Person purchased shares, Series A Warrants and Series B Warrants as part of a private placement for an aggregate price of $65,000. Read SEC document |
| November 11, 2020 Filed Nov 13, 2020 17:17 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | GrantEmployee Stock Option (right to buy) · Derivative | 130,000 | $0.00 Strike: $4.05 | $0.00 |
DisclosureSEC source: 0001140361-20-025546 · form4.xml · derivative · entry 1 Sooch Mina · CIK 0001674006 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 130,000 shares Expires 2030-11-11 F1 · derivative.exercise_date: 2,700 shares vest each month-end from November 2020 through September 2024. The balance vests in October 2024. Read SEC document |
| November 05, 2020 Filed Nov 9, 2020 17:42 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | GrantEmployee Stock Option (right to buy) · Derivative | 158,475 | Not disclosed Strike: $1.21 | Not disclosed |
DisclosureSEC source: 0001596771-20-000109 · primary_doc.xml · derivative · entry 3 Sooch Mina · CIK 0001674006 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,475 Underlying: Common Stock · 158,475 shares Expires 2029-12-27 F1 · price: The reporting person acquired the shares and options to acquire shares of the common stock of Rexahn Pharmaceuticals, Inc. ("Rexahn") on November 5, 2020, in exchange for shares and options to acquire shares of the common stock of Ocuphire Pharma, Inc. ("Ocuphire"), pursuant to the Agreement and Plan of Merger and Reorganization, dated as of June 17, 2020, as amended, between Rexahn, Razor Merger Sub, Inc. and Ocuphire pursuant to which Ocuphire became a wholly-owned subsidiary of Rexahn. Per the terms of the Merger Agreement, each share of Ocuphire common stock was converted into the right to receive 1.0565 shares of Rexahn common stock. Subsequent to the merger, the name of the issuer was changed from Rexahn Pharmaceuticals, Inc. to Ocuphire Pharma, Inc. F3 · derivative.exercise_date: 19,017 shares vested on December 31, 2019, and the remaining shares vest in equal monthly installments from January 2020 through December 2021, subject to continued service. Read SEC document |
| November 05, 2020 Filed Nov 9, 2020 17:42 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | GrantEmployee Stock Option (right to buy) · Derivative | 178,284 | Not disclosed Strike: $0.90 | Not disclosed |
DisclosureSEC source: 0001596771-20-000109 · primary_doc.xml · derivative · entry 2 Sooch Mina · CIK 0001674006 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,284 Underlying: Common Stock · 178,284 shares Expires 2028-10-01 F1 · price: The reporting person acquired the shares and options to acquire shares of the common stock of Rexahn Pharmaceuticals, Inc. ("Rexahn") on November 5, 2020, in exchange for shares and options to acquire shares of the common stock of Ocuphire Pharma, Inc. ("Ocuphire"), pursuant to the Agreement and Plan of Merger and Reorganization, dated as of June 17, 2020, as amended, between Rexahn, Razor Merger Sub, Inc. and Ocuphire pursuant to which Ocuphire became a wholly-owned subsidiary of Rexahn. Per the terms of the Merger Agreement, each share of Ocuphire common stock was converted into the right to receive 1.0565 shares of Rexahn common stock. Subsequent to the merger, the name of the issuer was changed from Rexahn Pharmaceuticals, Inc. to Ocuphire Pharma, Inc. F2 · derivative.exercise_date: The option is fully vested. Read SEC document |
| November 05, 2020 Filed Nov 9, 2020 17:42 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | GrantCommon Stock | 788,520 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001596771-20-000109 · primary_doc.xml · nonDerivative · entry 1 Sooch Mina · CIK 0001674006 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 788,520 F1 · price: The reporting person acquired the shares and options to acquire shares of the common stock of Rexahn Pharmaceuticals, Inc. ("Rexahn") on November 5, 2020, in exchange for shares and options to acquire shares of the common stock of Ocuphire Pharma, Inc. ("Ocuphire"), pursuant to the Agreement and Plan of Merger and Reorganization, dated as of June 17, 2020, as amended, between Rexahn, Razor Merger Sub, Inc. and Ocuphire pursuant to which Ocuphire became a wholly-owned subsidiary of Rexahn. Per the terms of the Merger Agreement, each share of Ocuphire common stock was converted into the right to receive 1.0565 shares of Rexahn common stock. Subsequent to the merger, the name of the issuer was changed from Rexahn Pharmaceuticals, Inc. to Ocuphire Pharma, Inc. Read SEC document |
| January 02, 2019 Filed Feb 5, 2019 15:37 UTC | BIOVIE INC. bivi · Entity 7702 | GrantCommon Stock | 200,000 | $0.04 | $7,000.00 |
DisclosureSEC source: 0001674006-19-000001 · primary_doc.xml · nonDerivative · entry 1 Sooch Mina · CIK 0001674006 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 813,636 Read SEC document |
| April 30, 2018 Filed Aug 14, 2018 18:14 UTC | BIOVIE INC. bivi · Entity 7702 | Grantcommon stock | 150,000 | $0.02 | $3,600.00 |
DisclosureSEC source: 0001674006-18-000003 · primary_doc.xml · nonDerivative · entry 2 Sooch Mina · CIK 0001674006 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 613,636 Read SEC document |
| January 02, 2018 Filed Aug 14, 2018 18:14 UTC | BIOVIE INC. bivi · Entity 7702 | Grantcommon stock | 200,000 | $0.15 | $30,000.00 |
DisclosureSEC source: 0001674006-18-000003 · primary_doc.xml · nonDerivative · entry 1 Sooch Mina · CIK 0001674006 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 463,636 Read SEC document |
| November 25, 2016 Filed Nov 29, 2016 16:29 UTC | MetaVia Inc. GEMP · Entity 7947 | GrantEmployee Stock Option (right to buy) · Derivative | 120,000 | $0.00 Strike: $10.00 | $0.00 |
DisclosureSEC source: 0001596771-16-000166 · primary_doc.xml · derivative · entry 1 Sooch Mina · CIK 0001674006 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600,000 Underlying: Common Stock · 120,000 shares Expires 2026-08-03 F1 · shares: The reporting person was granted an option to purchase 600,000 shares of common stock effective August 4, 2016. 360,000 of the shares underlying the option award were immediately earned on the date of the grant, 120,000 shares underlying the option award were earned on September 30, 2016 following the initiation of the Company's first clinical trial and 120,000 shares underlying the option award are earned upon the initiation of the Company's second clinical trial. The Company has initiated its second clinical trial, so the 120,000 shares underlying the option award that were subject to the initiation of the Company's second clinical trial have been earned. F2 · derivative.exercise_date: The option vests in 48 equal consecutive monthly increments, so that all of the shares will be vested on the fourth anniversary of the date of grant. F1 · balance_after: The reporting person was granted an option to purchase 600,000 shares of common stock effective August 4, 2016. 360,000 of the shares underlying the option award were immediately earned on the date of the grant, 120,000 shares underlying the option award were earned on September 30, 2016 following the initiation of the Company's first clinical trial and 120,000 shares underlying the option award are earned upon the initiation of the Company's second clinical trial. The Company has initiated its second clinical trial, so the 120,000 shares underlying the option award that were subject to the initiation of the Company's second clinical trial have been earned. Read SEC document |
| September 30, 2016 Filed Oct 3, 2016 16:32 UTC | MetaVia Inc. GEMP · Entity 7947 | GrantEmployee Stock Option (right to buy) · Derivative | 120,000 | $0.00 Strike: $10.00 | $0.00 |
DisclosureSEC source: 0001596771-16-000157 · primary_doc.xml · derivative · entry 1 Sooch Mina · CIK 0001674006 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 480,000 Underlying: Common Stock · 120,000 shares Expires 2026-08-03 F1 · shares: The reporting person was granted an option to purchase 600,000 shares of common stock effective August 4, 2016. 360,000 of the shares underlying the option award were immediately earned on the date of grant, 120,000 shares underlying the option award are earned upon the initiation of the Company's first clinical trial and 120,000 shares underlying the option award are earned upon the initiation of the Company's second clinical trial. The Company has initiated its first clinical trial, so the 120,000 shares underlying the option award that were subject to the initiation of the Company's first clinical trial have been earned. F2 · derivative.exercise_date: The option vests in 48 equal consecutive monthly increments, so that all of the shares will be vested on the fourth anniversary of the date of grant. F1 · balance_after: The reporting person was granted an option to purchase 600,000 shares of common stock effective August 4, 2016. 360,000 of the shares underlying the option award were immediately earned on the date of grant, 120,000 shares underlying the option award are earned upon the initiation of the Company's first clinical trial and 120,000 shares underlying the option award are earned upon the initiation of the Company's second clinical trial. The Company has initiated its first clinical trial, so the 120,000 shares underlying the option award that were subject to the initiation of the Company's first clinical trial have been earned. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.